What's breaking now, across thousands of outlets.
Keytruda SC, an immune-oncology drug incorporating Alteogen’s core technology, has been pulled from sale in several European countries amid a patent dispute. Concerns that the legal battle involving U.S. partner Merck (MSD) could affect Alteogen’s revenue structure sent the company’s share price dow
We haven't written up this one. BusinessKorea has the full story — the link below goes straight to it.
(RTTNews) - European stocks may drift lower at open on Thursday, with technology stocks likely to be in focus after the Wall Street Journal reported that SpaceX, Broadcom and Oracle were looking to…
On a review of current and evolving liquidity conditions, it has been decided to conduct a second Variable Rate Reverse Repo (VRRR) auction on Thursday, October 08, 2026, as under: Sl. No.
The introduction of a merchant discount rate (MDR) on select UPI transactions may be deferred from October 15 to January…
Tencent Holdings Ltd. is considering an offshore bond sale of as much as $5 billion, according to people familiar with the matter, adding to the wave of tech companies seeking debt financing as…
India is considering delaying the rollout of a fee on large payments via its popular Unified Payment Interface platform by a few months, according to a regulatory official and an industry executive…
